Pay‑to‑test Gene Therapies Hide Risk

Updated: 2026.11.18 1H ago 1 sources
Private payments for experimental, customized gene therapies can create perverse incentives: families pay large sums to high‑profile labs, hospitals rubber‑stamp treatments despite incomplete toxicology, and adverse events go undisclosed, producing a shadow clinical research market. This dynamic undermines informed consent, corrupts institutional review, and creates data that may be unreliable for regulators and foreign partners. — If pay‑to‑participate practices are common, they alter the ethics and reliability of clinical research and demand policy responses from national regulators and international partners who rely on those data.

Sources

What China’s Gene-Editing Deaths Reveal About Its Biotech Industry
Jane Qiu 2026.11.18 100% relevant
The article’s central case: parents paid Professor Qiu $860,000 for a bespoke AAV gene editor therapy for their child (event: March 24, 2025 injection; actor: Shanghai Jiao Tong University team; corroborating evidence: Science and Shanghai municipal investigations reporting non‑disclosure and failed toxicology).
← Back to all ideas